Standout Papers

PTEN activation contributes to tumor inhibition by ... 1986 2026 1999 2012 1.4k
  1. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients (2004)
    Yoichi Nagata, Keng‐Hsueh Lan et al. Cancer Cell
  2. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition (2004)
    Binhua P. Zhou, Jiong Deng et al. Nature Cell Biology
  3. Requirement for neuregulin receptor erbB2 in neural and cardiac development (1995)
    Kuo-Fen Lee, Horst H. Simon et al. Nature
  4. The neu oncogene encodes an epidermal growth factor receptor-related protein (1986)
    Cornelia I. Bargmann, Mien‐Chie Hung et al. Nature
  5. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells (2001)
    Binhua P. Zhou, Yong Liao et al. Nature Cell Biology
  6. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 (1986)
    Cornelia I. Bargmann, Mien‐Chie Hung et al. Cell
  7. Nuclear localization of EGF receptor and its potential new role as a transcription factor (2001)
    Shiaw‐Yih Lin, Keishi Makino et al. Nature Cell Biology
  8. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression (2017)
    Shiping Jiao, Weiya Xia et al. Clinical Cancer Research
  9. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation (2001)
    Binhua P. Zhou, Yong Liao et al. Nature Cell Biology
  10. IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a (2004)
    Mickey C.‐T. Hu, Dung‐Fang Lee et al. Cell
  11. BAP1 links metabolic regulation of ferroptosis to tumour suppression (2018)
    Yilei Zhang, Jiejun Shi et al. Nature Cell Biology
  12. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer (2006)
    Rita Nahta, Dihua Yu et al. Nature Clinical Practice Oncology
  13. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. (1997)
    Janusz Rak, Mien‐Chie Hung et al. PubMed
  14. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer (2009)
    Sao Jiralerspong, Shana L. Palla et al. Journal of Clinical Oncology
  15. Mechanisms Controlling PD-L1 Expression in Cancer (2019)
    Jong‐Ho Cha, Li-Chuan Chan et al. Molecular Cell
  16. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression (2000)
    Shiaw‐Yih Lin, Weiya Xia et al. Proceedings of the National Academy of Sciences
  17. Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer (2013)
    Chenfang Dong, Tingting Yuan et al. Cancer Cell
  18. p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs (2011)
    Chun-Ju Chang, Chi-Hong Chao et al. Nature Cell Biology
  19. Long noncoding RNA MALAT1 suppresses breast cancer metastasis (2018)
    Jongchan Kim, Hai-long Piao et al. Nature Genetics
  20. Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues (2002)
    Shuyuan Yeh, Qingquan Xu et al. Proceedings of the National Academy of Sciences
  21. Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression (2007)
    Hui‐Wen Lo, Sheng-Chieh Hsu et al. Cancer Research
  22. Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin (2005)
    Qingqing Ding, Weiya Xia et al. Molecular Cell
  23. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy (2021)
    Ri‐Yao Yang, Linlin Sun et al. Nature Communications
  24. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion (2018)
    Jung-Mao Hsu, Weiya Xia et al. Nature Communications
  25. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics (2022)
    Hirohito Yamaguchi, Jung-Mao Hsu et al. Nature Reviews Clinical Oncology
  26. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade (2019)
    Ying Zhu, Jing Yang et al. Gut
  27. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis (2020)
    Daqian Xu, Zheng Wang et al. Nature
  28. TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis (2021)
    Zhou Jiang, Seung-Oe Lim et al. Journal of Clinical Investigation
  29. Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity (2021)
    Junwei Hou, Jung-Mao Hsu et al. Molecular Cell
  30. Advances and prospects of biomarkers for immune checkpoint inhibitors (2024)
    Hirohito Yamaguchi, Jung-Mao Hsu et al. Cell Reports Medicine

Immediate Impact

4 by Nobel laureates 62 from Science/Nature 115 standout
Sub-graph 1 of 18

Citing Papers

DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer
2021 StandoutNature
Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
2019 StandoutNature
2 intermediate papers

Works of Mien‐Chie Hung being referenced

BAP1 links metabolic regulation of ferroptosis to tumour suppression
2018 Standout
MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation
2006
and 1 more

Author Peers

Author Last Decade Papers Cites
Mien‐Chie Hung 42788 27578 13565 740 66.0k
Carlos Cordon‐Cardo 40955 22560 12688 563 67.3k
Lance A. Liotta 34161 16682 16679 650 61.2k
Gordon B. Mills 56742 26097 20496 1.0k 87.5k
John D. Minna 41701 26002 13132 784 72.6k
Carl‐Henrik Heldin 41421 13948 8881 492 62.1k
Darell D. Bigner 21817 15412 10269 619 47.4k
Napoleone Ferrara 60705 20350 23583 257 97.7k
Judah Folkman 62209 24238 29198 391 103.7k
Peter Carmeliet 52350 14817 27080 720 98.1k
David P. Lane 37043 31996 8635 606 57.0k

All Works

Loading papers...

Rankless by CCL
2026